ERBB2 and breast carcinoma: Trastuzumab (herceptin) is a monoclonal antibody which targets HER2 and combination chemotherapy with trastuzumab is now a standard first-line treatment for women with advanced HER2 overexpressing breast cancer (Vogel et al, 2002).